Joel Isaacson & Co’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $231K | Sell |
2,375
-450
| -16% | -$42.2K | 0.01% | 448 |
|
|
2026
Q2 | $253K | Sell |
2,825
-200
| -7% | -$16.5K | 0.01% | 417 |
|
|
2026
Q1 | $240K | Hold |
3,025
| – | – | 0.01% | 403 |
|
|
2025
Q4 | $249K | Hold |
3,025
| – | – | 0.01% | 397 |
|
|
2025
Q3 | $211K | Buy |
+3,025
| New | +$204K | 0.01% | 420 |
|
|
2025
Q2 | – | Sell |
-6,730
| Closed | -$427K | – | 430 |
|
|
2025
Q1 | $427K | Hold |
6,730
| – | – | 0.02% | 258 |
|
|
2024
Q4 | $448K | Hold |
6,730
| – | – | 0.02% | 245 |
|
|
2024
Q3 | $470K | Hold |
6,730
| – | – | 0.02% | 232 |
|
|
2024
Q2 | $436K | Hold |
6,730
| – | – | 0.02% | 237 |
|
|
2024
Q1 | $436K | Hold |
6,730
| – | – | 0.02% | 229 |
|
|
2023
Q4 | $443K | Hold |
6,730
| – | – | 0.03% | 205 |
|
|
2023
Q3 | $384K | Hold |
6,730
| – | – | 0.03% | 218 |
|
|
2023
Q2 | $412K | Hold |
6,730
| – | – | 0.03% | 211 |
|
|
2023
Q1 | $422K | Hold |
6,730
| – | – | 0.03% | 204 |
|
|
2022
Q4 | $427K | Hold |
6,730
| – | – | 0.03% | 203 |
|
|
2022
Q3 | $397K | Hold |
6,730
| – | – | 0.03% | 190 |
|
|
2022
Q2 | $389K | Hold |
6,730
| – | – | 0.03% | 191 |
|
|
2022
Q1 | $408K | Hold |
6,730
| – | – | 0.03% | 207 |
|
|
2021
Q4 | $479K | Hold |
6,730
| – | – | 0.03% | 191 |
|
|
2021
Q3 | $504K | Hold |
6,730
| – | – | 0.04% | 180 |
|
|
2021
Q2 | $520K | Hold |
6,730
| – | – | 0.04% | 173 |
|
|
2021
Q1 | $497K | Hold |
6,730
| – | – | 0.04% | 156 |
|
|
2020
Q4 | $472K | Hold |
6,730
| – | – | 0.05% | 153 |
|
|
2020
Q3 | $381K | Hold |
6,730
| – | – | 0.05% | 151 |
|
|
2020
Q2 | $392K | Hold |
6,730
| – | – | 0.06% | 138 |
|
|
2020
Q1 | $313K | Hold |
6,730
| – | – | 0.05% | 135 |
|
|
2019
Q4 | $376K | Hold |
6,730
| – | – | 0.05% | 152 |
|
|
2019
Q3 | $319K | Hold |
6,730
| – | – | 0.05% | 159 |
|
|
2019
Q2 | $360K | Hold |
6,730
| – | – | 0.05% | 148 |
|
|
2019
Q1 | $371K | Hold |
6,730
| – | – | 0.05% | 153 |
|
|
2018
Q4 | $350K | Hold |
6,730
| – | – | 0.06% | 161 |
|
|
2018
Q3 | $400K | Hold |
6,730
| – | – | 0.06% | 144 |
|
|
2018
Q2 | $368K | Hold |
6,730
| – | – | 0.06% | 146 |
|
|
2018
Q1 | $331K | Hold |
6,730
| – | – | 0.06% | 146 |
|
|
2017
Q4 | $317K | Hold |
6,730
| – | – | 0.06% | 147 |
|
|
2017
Q3 | $336K | Hold |
6,730
| – | – | 0.06% | 140 |
|
|
2017
Q2 | $307K | Hold |
6,730
| – | – | 0.06% | 142 |
|
|
2017
Q1 | $285K | Sell |
6,730
-160
| -2% | -$6.71K | 0.06% | 140 |
|
|
2016
Q4 | $267K | Hold |
6,890
| – | – | 0.05% | 134 |
|
|
2016
Q3 | $289K | Hold |
6,890
| – | – | 0.06% | 138 |
|
|
2016
Q2 | $255K | Hold |
6,890
| – | – | 0.05% | 145 |
|
|
2016
Q1 | $264K | Hold |
6,890
| – | – | 0.06% | 146 |
|
|
2015
Q4 | $348K | Hold |
6,890
| – | – | 0.09% | 110 |
|
|
2015
Q3 | $315K | Hold |
6,890
| – | – | 0.08% | 110 |
|
|
2015
Q2 | $402K | Hold |
6,890
| – | – | 0.1% | 99 |
|
|
2015
Q1 | $380K | Hold |
6,890
| – | – | 0.1% | 104 |
|
|
2014
Q4 | $346K | Hold |
6,890
| – | – | 0.09% | 103 |
|
|
2014
Q3 | $318K | Hold |
6,890
| – | – | 0.1% | 86 |
|
|
2014
Q2 | $301K | Hold |
6,890
| – | – | 0.09% | 94 |
|
|
2014
Q1 | $287K | Buy |
+6,890
| New | +$295K | 0.1% | 94 |
|
Other funds holding PBE
Joel Isaacson & Co's PBE Position: Q3 2026 in Review
Joel Isaacson & Co reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 16% in Q3 2026, selling an estimated $42.2K and leaving 2,375 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #448.
Joel Isaacson & Co first reported a position in PBE in Q1 2014 and has held it in 50 quarters since. The position peaked at $520K in Q2 2021. 51 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Joel Isaacson & Co held 2,375 shares of Invesco Biotechnology & Genome ETF worth $231K as of Q3 2026.
- Joel Isaacson & Co sold 450 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $42.2K.
- Invesco Biotechnology & Genome ETF made up 0.01% of Joel Isaacson & Co's portfolio in Q3 2026, its #448 holding.
- Joel Isaacson & Co first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and has held it in 50 quarters since.
- Joel Isaacson & Co's Invesco Biotechnology & Genome ETF position peaked at $520K in Q2 2021.
- 51 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Joel Isaacson & Co's 13F filing for Q3 2026, filed 5 Nov 2026.